Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Tarlatamab + AB248 Studied In Extensive Stage Small Cell Lung Cancer
Details : Tarlatamab is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 25, 2025
AB821 in Adult Participants with Locally Advanced or Metastatic Solid Tumors
Details : AB821 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 18, 2025
Lead Product(s) : Etakafusp Alpha,Tarlatamab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Asher Bio, BeiGene Collaborate on AB248, T-Cell Engager for Lung Cancer
Details : As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study to evaluate the early efficacy of AB248 (etakafusp alfa) in combination with Imdelltra in patients with ES-SCLC.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Etakafusp Alpha,Tarlatamab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Etakafusp Alpha,Rilvegostomig
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement
Asher Bio, BeiGene Collaborate on AB248 Phase 1b/2 NSCLC Clinical Trial
Details : As part of this agreement, AstraZeneca will operationalize a global study of AB248 (etakafusp alfa) as a first-line treatment in combination with rilvegostomig in patients with advanced NSCLC.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
January 07, 2025
Lead Product(s) : Etakafusp Alpha,Rilvegostomig
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Etakafusp Alpha,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : RA Capital Management
Deal Size : $55.0 million
Deal Type : Series C Financing
Asher Bio Closes $55 Million Series C Financing for Trials
Details : AB248, a novel IL-2 mutein fused to anti-CD8β antibody, is in Phase 1 trials as a CD8+ T cell selective IL-2 for cancer treatment.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Etakafusp Alpha,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : RA Capital Management
Deal Size : $55.0 million
Deal Type : Series C Financing
Lead Product(s) : Etakafusp Alpha,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB248 is a novel CD8+ T cell selective IL-2, it selectively and potently activate CD8+ T-cells, while avoiding NK cells, which can act as pharmacological sink and contribute to toxicity, and regulatory T (Treg) cells, which are immunosuppressive.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Etakafusp Alpha,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etakafusp Alfa
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Etakafusp Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 16, 2022
Lead Product(s) : Etakafusp Alfa
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB821
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB821, a CD8-IL21 cytokine has the potential to treat tumor types that may not be responsive to IL-2 and/or PD-1 therapy. PD-1-resistant tumors are associated with reduced memory T cell numbers and increased exhausted T cell numbers.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 03, 2022
Lead Product(s) : AB821
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB359
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB359, a CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infections is potentially more tolerable and more active IL‑2-based therapy for the treatment of chronic HBV.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : AB359
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etakafusp Alpha
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB248, Asher Bio’s lead cis-targeted immunotherapy, is a novel CD8-targeted IL-2 mutein designed to selectively activate interleukein-2 (IL-2) signaling on CD8+ T cells over natural killer cells and regulatory T (Treg) cells.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : Etakafusp Alpha
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable